Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.44 |
| ▸ | NPC1 | O15118 | 5/20 | 0.44 |
| ▸ | HPGD | P15428 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CCR2 | P41597 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | GCGR | P47871 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2650123 | 1.00 | RAB9A (0.44) | RAB9ANPC1HPGDSMN1; SMN2TP53 | |
| SCHEMBL2665117 | 1.00 | RAB9A (0.44) | RAB9ANPC1HPGDSMN1; SMN2TP53 | |
| SCHEMBL2664958 | 0.88 | GCGR (0.45) | RAB9ANPC1SMN1; SMN2GCGRALDH1A1 | |
| SCHEMBL2649603 | 0.88 | GCGR (0.45) | RAB9ANPC1SMN1; SMN2GCGRALDH1A1 | |
| SCHEMBL2647340 | 0.88 | GCGR (0.45) | RAB9ANPC1SMN1; SMN2GCGRALDH1A1 | |
| SCHEMBL2649608 | 0.88 | GCGR (0.45) | RAB9ANPC1SMN1; SMN2GCGRALDH1A1 | |
| SCHEMBL2647338 | 0.88 | GCGR (0.45) | RAB9ANPC1SMN1; SMN2GCGRALDH1A1 | |
| SCHEMBL6914043 | 0.87 | DHODH (0.40) | RAB9ANPC1GCGRKMT2A | |
| SCHEMBL6914039 | 0.87 | DHODH (0.40) | RAB9ANPC1GCGRKMT2A | |
| SCHEMBL2665118 | 0.85 | SMN1; SMN2 (0.47) | RAB9ANPC1SMN1; SMN2GCGRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1463715-A1 | NOVEL GLUCAGON ANTAGONISTS | NOVO NORDISK A/S (DK) | 2004-10-06 | — | — | EP | disclosed |
| US-6762318-B2 | CARBOXYLIC ACID OR TETRAZOLE DERIVATIZED SECONDARY AMIDES; ORAL ADMINISTRATION | NOVO NORDISK A/S (DK) | 2004-07-13 | — | — | US | disclosed |
| US-20030236292-A1 | Stimulant releasing glucose from liver cells; antidiabetic agents | PFIZER INC | 2003-12-25 | — | — | US | disclosed |
| WO-2003048109-A1 | NOVEL GLUCAGON ANTAGONISTS | NOVO NORDISK A/S (DK) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236292-A1 | Stimulant releasing glucose from liver cells; antidiabetic agents | GPR119, GLP1R, GIPR | RAB9A 3070/4885NPC1 1374/4885HPGD 3322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.